Market revenue in 2023 | USD 13.4 million |
Market revenue in 2030 | USD 23.1 million |
Growth rate | 8.1% (CAGR from 2023 to 2030) |
Largest segment | Mrna reprogramming |
Fastest growing segment | MRNA Reprogramming |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Mrna reprogramming was the largest segment with a revenue share of 32.09% in 2023. Horizon Databook has segmented the Italy cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
Market players, such as Merck KGaA and REPROCELL Europe Ltd., are implementing numerous strategies in Italy to leverage the untapped opportunities in the market. For instance, in October 2022, Segment, a division of REPROCELL, introduced mRNA reprogramming to the clinical sector, providing a nonviral and non-retained approach for the reliable, rapid, and safe production of human iPSC lines.
This clinical-grade iPSC generation method utilizes mRNA reprogramming technology, overcoming the limitations associated with viral or DNA vector-based reprogramming approaches. Widely recognized for its productivity and suitability in creating footprint-free iPSCs, this technology is an optimal solution for clinical iPSC production.
Horizon Databook provides a detailed overview of country-level data and insights on the Italy cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into Italy cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account